LL-37, Human

Research use only, not for human use.

LL-37, Human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity.

LL-37, Human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity.

LL-37, human (1-20 μg/mL; 24 h) affects HCECs migration.LL-37, human (0.0001-5 μg/mL;6-24 h) affects cytokine secretion in HCECs.LL-37, human (1-100 μg/mL; 24 h) shows dose-dependently cytotoxic to HCECs at concentrations over 10 μg /mL. Cell Migration Assay Cell Line:Human corneal epithelial cell (HCEC)Concentration:1, 2.5, 5, 10 and 20 μg/mL Incubation Time:24 hoursResult:Dose-dependently stimulated HCEC migration but showed no effect on cell proliferation.Cell Viability Assay Cell Line:Human corneal epithelial cell (HCEC) Concentration:0.0001, 0.001, 0.01, 0.1, 0.5, 1, and 5 μg/mL Incubation Time:6 and 24 hours Result:Dose-dependently increased IL-8, IL-6, IL-1β and TNF-α secretion at 6 and 24 hours in HCEC.

LL-37, human (0.4-2.0 mg/kg; intratracheal injection once) ameliorates MRSA-induced pneumonia of mice. Animal Model:6-8 week-old C57BL/6 mice with MRSA-induced pneumonia Dosage:0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg Administration:Intratracheal injection; 0.4-2.0 mg/kg once Result:Decreased IL-6 and TNF-α release to attenuated MRSA-induced pneumonia of testing mice.

——

GPCR/G Protein

Antibacterial

——

——

——

154947-66-7

4493.26

C205H340N60O53

>98% (HPLC)

In Vitro:?H2O : 50 mg/mL (11.13 mM)

——

Sequence:{Leu}{Leu}{Gly}{Asp}{Phe}{Phe}{Arg}{Lys}{Ser}{Lys}{Glu}{Lys}{Ile}{Gly}{Lys}{Glu}{Phe}{Lys}{Arg}{Ile}{Val}{Gln}{Arg}{Ile}{Lys}{Asp}{Phe}{Leu}{Arg}{Asn}{Leu}{Val}{Pro}{Arg}{Thr}{Glu}{Ser}

(-20℃)

With Ice Pack

≥ 2 years